Congratulations to Adrian (Ad) Rawcliffe and the entire Adaptimmune team on the U.S. Food and Drug Administration (FDA) accelerated approval of TECELRA® (afamitresgene autoleucel). TECELRA is the first engineered cell therapy for a solid tumor cancer approved in the U.S., and the first new therapy option in more than a decade for synovial sarcoma, a rare, soft tissue cancer that most commonly impacts young adults. “The approval of TECELRA is a momentous step in Adaptimmune’s journey to redefine the way cancer is treated and the culmination of a decade of groundbreaking R&D. I want to thank the patients, caregivers, investigators, and clinical teams as well as everyone at Adaptimmune and our partners who made possible this watershed moment for cell therapy and for people with synovial sarcoma. We are committed to advancing our robust clinical pipeline to serve more patients in need and plan to progress lete-cel, the next late-stage investigational treatment in our sarcoma franchise, with a rolling BLA submission to the FDA next year,” said Adrian Rawcliffe, Adaptimmune's Chief Executive Officer. Learn more: https://lnkd.in/eHc8rAmt Alex Pasteur, Ph.D. │ Nihal Sinha, M.D. #healthcare #cancer #biotech #oncology
F-Prime Capital
Venture Capital and Private Equity Principals
Cambridge, MA 19,662 followers
We create and invest in healthcare and technology companies that impact lives all over the world.
About us
Our roots are in one of America’s great entrepreneurial success stories. Fidelity Investments was founded in 1946 and grew from a single mutual fund into one of the largest asset management firms in the world, with over $2 trillion in assets under management. For the last forty years, our venture capital group has had the privilege of backing other great entrepreneurs as they built ground-breaking companies in technology and life sciences, including Atari, MCI, ROLM Corp., Alibaba, Ironwood Pharmaceuticals, and Ultragenyx. Today our funds are larger and more global, but our teams are still small and local. We stay true to our entrepreneurial roots. In the US and Europe, we are F-Prime Capital investing in healthcare (formerly Fidelity Biosciences) and in technology (formerly part of Devonshire Investors). In other geographies, our sister fund is called Eight Roads (formerly Fidelity Growth Partners), with investment teams in London, Shanghai, Beijing, Hong Kong, Tokyo, and Mumbai. Together we bring a world of insight, domain expertise and relationships to support our entrepreneurs. Without the pressure of fundraising from outside investors, we focus all of our time finding and helping great entrepreneurs build important companies.
- Website
-
http://fprimecapital.com/
External link for F-Prime Capital
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 11-50 employees
- Headquarters
- Cambridge, MA
- Type
- Privately Held
Locations
-
Primary
One Main Street
Cambridge, MA 02142, US
Employees at F-Prime Capital
Updates
-
Earlier this week, our own Robert Weisskoff, Ph.D. was invited to the Gate Opening Summit for Innovative Drug Discovery. This event took place in Tokyo, Japan and gathered Japanese government officials, including Prime Minister Fumio Kishida, biotech industry experts, and representatives from major pharmaceutical organizations. The main objective of the event was to address the following key points: the challenges Japan faces in medication access and potential solutions, strategies for enhancing Japan's drug discovery efforts, and ways to advance their investment and innovation ecosystem. “The strategic goals and road maps we have announced today are a commitment to the people inside and outside of Japan that the government will materialize and advance efforts for drug discovery,” Prime Minister Fumio Kishida said Tuesday. To learn more about this Summit, please visit: https://bit.ly/46sqMbf #healthcare #biotech #pharmaceuticals
-
F-Prime Capital reposted this
Check out the latest funding news in the world of robotics. F-Prime Capital https://lnkd.in/ekGvUeXs
-
F-Prime Capital reposted this
I'm excited to join my Eight Roads colleagues in Mumbai on September 4 for #ScaleUpHealth2024, a forum for #healthtech builders to engage with policymakers and investors. I look forward to our panel, "Will India be swept up in the $100Bn global surge of anti-obesity drugs?" I hope to see you there! Sofitel, Bandra Kurla Complex, Mumbai https://lnkd.in/dtKBaMyR Prem Pavoor Ashish Venkataramani Chintan Kothari Diya Nayar
Scale-Up Health 2024
https://scaleuphealth.in
-
The Alzheimer's Association® International Conference (AAIC) 2024 kicks off today in Philadelphia and virtually. F-Prime’s Stacie Weninger, Ph.D. will be moderating a panel tomorow, Monday, July 29th to discuss "The Next Generation of Treatment and Prevention" with esteemed neurology and neuroscience professors from the U.S. and England. To learn more about this event, please visit: https://aaic.alz.org/ #AAIC24 #Alzheimers #Dementia #EndAlz
-
F-Prime Capital reposted this
🎉 One Year of FedNow: Instant Payments, Instant Insights! 🚀 Time flies in real-time! It’s been a year since the U.S. government launched FedNow, and I had the honor of joining the Wharton Fintech Podcast to chat with Nick Stanescu from the Federal Reserve Bank of Boston and Carlos Eduardo Brandt from Banco Central do Brasil. (➡ podcast link in comments!) I’ve distilled the learnings into my latest Forbes post. https://lnkd.in/gXiCcdnZ Here are some highlights: 📈 𝗠𝗮𝘀𝘀 𝗰𝗼𝗻𝗻𝗲𝗰𝘁𝗶𝘃𝗶𝘁𝘆 𝘄𝗶𝗹𝗹 𝘁𝗮𝗸𝗲 𝗮 𝗹𝗼𝗻𝗴 𝘁𝗶𝗺𝗲…With 900 financial institutions live on FedNow, we’re on a fast track— closer to five years away from widespread adoption instead of ten! 💲𝗠𝗲𝗿𝗰𝗵𝗮𝗻𝘁 𝗶𝗻𝗰𝗲𝗻𝘁𝗶𝘃𝗲𝘀: 𝗖𝗼𝘀𝘁 𝘀𝗮𝘃𝗶𝗻𝗴𝘀 𝗮𝗹𝗼𝗻𝗲 𝗮𝗿𝗲𝗻’𝘁 𝗲𝗻𝗼𝘂𝗴𝗵. Real-time payments need to boost conversion, loyalty, and customer satisfaction to win merchants over. 💸 𝗕𝗮𝗻𝗸 𝗶𝗻𝗰𝗲𝗻𝘁𝗶𝘃𝗲𝘀: 𝗛𝗼𝗽𝗽𝗶𝗻𝗴 𝘁𝗵𝗲 𝗿𝗲𝘃𝗲𝗻𝘂𝗲 𝗵𝘂𝗿𝗱𝗹𝗲. Banks see cost savings (checks, cash, ATM) but worry about lost revenue from traditional payment methods (wire, credit card interchange fees). Will FedNow steal the show? 🔐 𝗦𝗲𝗰𝘂𝗿𝗶𝘁𝘆 𝗶𝘀 𝗮 𝗺𝗼𝘃𝗶𝗻𝗴 𝘁𝗮𝗿𝗴𝗲𝘁. Real-time payments mean real-time security challenges. From social engineering to physical robbery, the threats evolve as fast as the payments. Do you know the Brazilian Public Security Yearbook counted around 1M phone robberies last year? 📱 𝗧𝗮𝗽-𝘁𝗼-𝗣𝗮𝘆 𝗰𝗼𝘂𝗹𝗱 𝗹𝗲𝘃𝗲𝗹 𝘁𝗵𝗲 𝗽𝗹𝗮𝘆𝗶𝗻𝗴 𝗳𝗶𝗲𝗹𝗱 𝗳𝗼𝗿 𝗼𝗳𝗳𝗹𝗶𝗻𝗲 𝗣𝗼𝗦 𝗽𝗮𝘆𝗺𝗲𝗻𝘁𝘀. With Apple enabling tap-to-pay and Face ID to non-Apple wallets in EU and NFC's new multi-purpose tap (pay for goods + check ID + loyalty points + digital receipt), offline POS payments are about to get a major upgrade. Dive into the full discussion on my Forbes post and the podcast. Let’s keep the real-time conversation going! 😉 #FedNow #Oneyear #RealTimePayments #InstantPayments #RTP #Fintech #Podcast
-
Check out the latest piece by LSI’s Henry Peck, where he delves into the thought process behind medtech and healthtech industry investors who sometimes must prioritize between the quality of a founding team and the size of the market potential. Within the article, our own Kevin Chu, a Principal on our team focused on healthcare investments within the therapeutics, medical devices, and life science sectors, provided his industry insights. Kevin shares his own philosophy when it comes to venture investing, emphasizing that while sheer market potential is important, maximizing clinical benefit is the most critical, even if that means prioritizing a narrower indication, and that, more often than not, high quality teams are most adept at quickly finding this balance. See the link in comments to learn more. #healthcare #medtech #healthtech #venturecapital
-
F-Prime Capital reposted this
We are excited to announce that CHARM Therapeutics has been featured as the highest rated drug discovery company in Sifted’s latest roundup of drug discovery companies to watch. The companies were selected based on a range of criteria across the following categories: funding history, investor prominence, growth, traction, and founder strength. CHARM Therapeutics stands out among these top AI companies in part due to DragonFold, our advanced protein-ligand intelligence platform which uses deep learning AI technology to design, test and optimize new molecules for previously undruggable targets with unprecedented precision to develop impactful medicines, but also reflects the strength of our high energy, talented team. Find the full list of Sifted’s start-ups to watch here: https://lnkd.in/eimQzZ8X #deeplearning #AI
-
Congratulations to Dr. Juergen Horn and the Invetx team on your acquisition by Dechra Pharmaceuticals. The combination of Invetx’s treatments for canine and feline chronic disease and Dechra’s specialty animal therapeutics business will help to improve the health and well-being of many animals in veterinary care. “We are thrilled to be joining forces with Dechra Pharmaceuticals, a global leader in animal health. Our pipeline of monoclonal antibody therapeutics for chronic, serious diseases in cats and dogs is highly complementary to Dechra’s broad portfolio of specialty therapeutics for companion animals and accelerates Dechra’s differentiated position in the veterinary health industry,” said Juergen Horn, Dr.med.vet., Ph.D., CEO and Founder of Invetx. Learn more: https://lnkd.in/egbhshV8 Anterra Capital │ Casdin Capital, LLC │ Eight Roads │ GV (Google Ventures) │ Novo Growth Partners, Inc. │ Tekla Capital Management Ketan Patel, M.D. │ Jessica Alston, Ph.D. │ Nikhil Ananth #veterinary #veterinarymedicine
-
Travel tech investment has been through a roller coaster of late. And while the market has cooled over the last couple of years, that isn't necessarily a bad thing. "We’ve only reverted to the levels we were at before a massive run up in the market," Gaurav recently told PhocusWire's Morgan Hines in an interview alongside Anna Schneider. "We're seeing great companies actually get funded now, and we're starting to wash through a lot of the noise and aftermath of the last two years." Check out the full interview and Phocuswire's summary via the links below👇